Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group HoldingsHKSE:06998 +0.33%15 Forward Dividend Yield % is 0.00% as of Aug. 27, 2026. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 505 Drug Manufacturers companies, Edding Genor Group Holdings ranks worse than 198019.6% on this metric.
HKSE:06998's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.99 * Ranked among companies with meaningful Forward Dividend Yield % only.
Edding Genor Group Holdings (HKSE:06998) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Edding Genor Group Holdings Forward Dividend Yield % Related Terms
HKSE:06998 vs ZTS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Edding Genor Group Holdings (HKSE:06998) has a Forward Dividend Yield % of 0.00% as of Aug. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Edding Genor Group Holdings and its competitors. According to the industry distribution chart, Edding Genor Group Holdings ranks #999999 out of 505 companies in the Drug Manufacturers industry.
Is Edding Genor Group Holdings' Forward Dividend Yield % too high?
Edding Genor Group Holdings' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Edding Genor Group Holdings ranks #999999 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #999999 out of 505 companies for Forward Dividend Yield %. This places Edding Genor Group Holdings in the lower half of its industry. The industry median Forward Dividend Yield % is 1.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 1.99, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current Forward Dividend Yield % is 0.00% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
